- In April 2024, the Moroccan Ministry of Health announced a strategic partnership with local and international healthcare providers to expand the availability of parenteral nutrition solutions in public hospitals. This initiative focuses on strengthening neonatal and intensive care units across the country by equipping them with advanced parenteral nutrition delivery systems. The move underscores the government’s commitment to improving patient outcomes through targeted nutrition therapy, especially among vulnerable populations
- In March 2024, Laprophan, a leading pharmaceutical manufacturer in Morocco, launched a new range of customized parenteral nutrition formulations designed for oncology and critical care patients. These advanced solutions are tailored to individual metabolic needs, supporting personalized medicine practices within Moroccan healthcare. This development highlights Laprophan’s role in driving local innovation and enhancing clinical nutrition standards
- In February 2024, the University Hospital of Rabat implemented an advanced clinical nutrition protocol incorporating real-time patient monitoring for those receiving total parenteral nutrition (TPN). Supported by digital health tools, the initiative aims to reduce complications, improve dosage precision, and streamline interdisciplinary care for ICU patients. This pilot project reflects a growing emphasis on technology-driven healthcare delivery in Morocco’s tertiary institutions
- In January 2024, a public-private collaboration between Nutricia (a Danone subsidiary) and several Moroccan teaching hospitals launched a training program for clinical nutritionists and pharmacists on the safe administration of parenteral nutrition. The program emphasizes evidence-based practices, risk management, and pediatric nutrition, contributing to capacity-building and professional development in the field
- In December 2023, Pharma 5, one of Morocco’s largest pharmaceutical companies, initiated plans to establish a dedicated production unit for sterile parenteral nutrition components within its Casablanca facility. The investment aims to reduce dependency on imports and improve the affordability and availability of essential intravenous nutrition products nationwide, marking a major step toward pharmaceutical self-sufficiency in the country
